PD-RAD sample analysis

  • Research type

    Research Study

  • Full title

    PD-RAD sample analysis: A translational study investigating immune changes in tumour and blood after radiotherapy in non-small cell lung cancer (NSCLC) using samples from the PD-RAD trial

  • IRAS ID

    297993

  • Contact name

    Tim Illidge

  • Contact email

    tim.illidge@manchester.ac.uk

  • Sponsor organisation

    The University of Manchester

  • Duration of Study in the UK

    2 years, 0 months, 0 days

  • Research summary

    Radiotherapy (RT) has been shown to have both positive and negative immune effects on the tumour microenvironment. Whilst immune checkpoint inhibition has been shown to enhance the efficacy of RT in some murine models, it is hypothesised that those tumours with low numbers of infiltrating T-cells or large numbers of immunosuppressive myeloid cells might benefit from combining different immuno-oncology (IO) agents with RT. Thus it is important to determine what effects RT has on the tumour immune microenvironment and identify immune biomarkers which might predict which IO agent to combine with RT.

    Furthermore, investigating systemic immune changes in peripheral blood and comparing them to those seen in the tumour may help in the identification of non-invasive biomarkers which are reflective of changes in the tumour.

    The PD-RAD study was a translational study looking at upregulation of PD-L1 after radiotherapy in patients with NSCLC. Patients consented to donate a diagnostic biopsy and an additional biopsy during the second week of radiotherapy, along with regular blood samples. Tumour biopsies were formalin fixed and embedded in paraffin, PBMC and plasma were isolated from peripheral blood and tempus tubes were stored for future isolation of RNA from blood. During the study RNA was extracted from tumour biopsies and stored for future research.
    We wish to continue analysis of these samples to look for RT induced changes and potential biomarkers of RT induced changes or response. The results from this study will increase our understanding of the immune response to radiotherapy, and guide future research studies.

  • REC name

    Yorkshire & The Humber - Leeds West Research Ethics Committee

  • REC reference

    21/YH/0289

  • Date of REC Opinion

    22 Nov 2021

  • REC opinion

    Favourable Opinion